Background and Aim
Abbreviations:Inflammatory bowel disease (IBD), colitis-associated neoplasia (CAN), endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), ulcerative colitis (UC), colorectal cancer (CRC), high-grade dysplasia (HGD), Crohn’s disease (CD), ulcerative colitis endoscopic index of severity (UCEIS), the ulcerative colitis colonoscopic index of severity (UCCIS), Crohn's disease endoscopic index of severity (CDEIS), simple endoscopic score for Crohn's disease (SES-CD), high-risk colitis-associated neoplasia (HR-CAN), low-grade dysplasia (LGD), Large non-pedunculated colorectal polyps (LNPCPs), colorectal neoplasia (CRN), adenoma detection rate (ADR), deep submucosal invasion (DSI), lymph node metastasis (LNM), endoscopic full-thickness resection (eFTR), endoscopic intermuscular dissection (EID), piecemeal endoscopic mucosal resection (pEMR), underwater endoscopic mucosal resection (U-EMR), European Society of Gastrointestinal Endoscopy (ESGE), American Society of Gastrointestinal Endoscopy (ASGE), advanced colorectal neoplasia (aCRN)
Publication stageIn Press Journal Pre-Proof
Source of support: None
Author contributions: MB contributed to the study design, collected data, conducted the analyses and drafted the manuscript. LM and BO contributed to the study design, provided important intellectual contributions, critically reviewed the manuscript and supervised the study. All other authors provided intellectual contributions and critically reviewed the manuscript. All authors approved the final version of the manuscript.
Financial conflict(s) of interest:
JE has served on clinical advisory boards for Paion; has served on the clinical advisory board and has share options in Satisfai Health; and reports speaker fees from Falk and Jannsen outside the submitted work. In addition, he is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. NCP is a consultant for Boston Scientific Corporation and Alexion Pharma; and has received research funding from Cook Endoscopy outside the submitted work. MK has equipment on loan from Fujifilm; he has received speaker’s fees from Boston Scientific, Ipsen, and Recordati, and a research grant from Olympus; he has provided consultancy for Olympus and ERBE outside the submitted work. AV has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer outside the submitted work. CW received research grants and/or fee for advisory boards and presentations from Pfizer, Abbvie, Celltrion, Falk Benelux, Takeda, Janssen, and Ferring outside the submitted work. RB has received research grants and speaker’s fees from Fujifilm, Norgine, and Pentax; he has provided consultancy for Fujifilm, Norgine, and Pentax outside the submitted work. AH has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Ferring, Galapogos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda outside the submitted work. She also serves on the Global Steering Committee for Genentech.SI has received consulting fees from Exact Sciences Corporation and Geneoscopy; and received unrestricted research grants from Exact Sciences Corporation and Freenome outside the submitted work. MP serves as a consultant for Boston Scientific Corporation and Norgine outside the submitted work. LM serves as a consultant for Boston Scientific Corporation outside the submitted work. All other authors have nothing to declare.
User licenseCreative Commons Attribution (CC BY 4.0) |
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy